Bulletin
Investor Alert

Market Pulse Archives

Oct. 19, 2017, 7:46 a.m. EDT

Corbus Pharma shares surge 21% on mid-stage results for inflammatory disease drug

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Corbus Pharmaceuticals Holdings Inc. (CRBP)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Emma Court

Corbus Pharmaceutical Holdings Inc. /zigman2/quotes/201549545/composite CRBP -0.27% shares surged 21.4% in premarket trade on Thursday after the company reported positive results from a phase 2 trial of its autoimmune disease drug. The drug, anabasum, is intended for the rare inflammatory condition dermatomyositis, which is associated with an itchy and painful rash and progressive muscle weakness, according to the Mayo Clinic. In the clinical trial, which enrolled 22 adults and lasted 16 weeks, the drug outperformed the placebo in the primary efficacy outcome and in multiple secondary efficacy outcomes, the company said. There were also no signs of safety issues, Corbus said. Currently, "we have little to offer patients with moderate to severe disease activity except immunosuppressive therapies with often limited efficacy and significant side effects," said Dr. Victoria Werth, a principal investigator in the study and a professor of dermatology at the Hospital of the University of Pennsylvania. Corbus Pharma shares have surged 6.9% over the last three months to $7.00 per share, compared with a 3.5% rise in the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.48% .

/zigman2/quotes/201549545/composite
US : U.S.: Nasdaq
$ 7.46
-0.02 -0.27%
Volume: 2.10M
May 29, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$540.78 million
Rev. per Employee
$62,627
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,044.31
+14.58 +0.48%
Volume: 4.38B
May 29, 2020 5:14p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.